

02/20/02
JC904 U.S. PTO

02-25-02

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>	Attorney Docket No.	BURF-P02-006
	First Inventor	Justin R. Fallon
	Title	Biglycan and Related Therapeutics and Methods of Use
	Express Mail Label No.	EL 805319583 US

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program <i>(Appendix)</i>
2. <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>
3. <input checked="" type="checkbox"/> Specification [Total Pages 90] <i>(preferred arrangement set forth below)</i> <ul style="list-style-type: none">- Descriptive title of the invention- Cross Reference to Related Applications- Statement Regarding Fed sponsored R & D- Reference to sequence listing, a table, or a computer program listing appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings <i>(if filed)</i>- Detailed Description- Claim(s)- Abstract of the Disclosure	a. <input type="checkbox"/> Computer Readable Form (CRF)
4. <input checked="" type="checkbox"/> Drawing(s) <i>(35 U.S.C. 113)</i> [Total Sheets 16]	b. Specification Sequence Listing on: <ul style="list-style-type: none">i. <input type="checkbox"/> CD-ROM or CD-R (2 copies)ii. <input checked="" type="checkbox"/> paper
5. Oath or Declaration [Total Pages 2] <ul style="list-style-type: none">a. <input type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i><ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	c. <input checked="" type="checkbox"/> Statements verifying identity of above copies
6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	

ACCOMPANYING APPLICATION PARTS	
9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))	
10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i>	
11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i>	
12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations	
13. <input type="checkbox"/> Preliminary Amendment	
14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>	
15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>	
16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.	
17. <input checked="" type="checkbox"/> Other: Certificate of Express Mail.	

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: **09/715,836**

Prior application information: Examiner _____ Group / Art Unit _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number or Bar Code Label  or <input type="checkbox"/> Correspondence address below <small>(Insert Customer No. or Attach bar code label here)</small>					
Name	Matthew P. Vincent PATENT TRADEMARK OFFICE				
	Ropes & Gray				
Address	IP Group One International Place				
City	Boston	State	MA	Zip Code	02110
Country	USA	Telephone	617 951 7000	Fax	617 951 7050

Name (Print/Type)	Matthew P. Vincent	Registration No. (Attorney/Agent)	36,709
Signature		Date	February 20, 2002

Burden Hour Statement This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Justin R. Fallon, et al.

Docket No.

BURF-P02-006

Serial No.

Not Yet Assigned

Filing Date

February 20, 2002

Examiner

Not Yet Assigned

Group Art Unit

Not Yet Assigned

Invention:


BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE

I hereby certify that the following correspondence:

Transmittal Letter (1 p.); New Continuation-In-Part Patent Application consisting of: 90 pp. specification; 16 Sheets of Formal Figures; 2 pp. unsigned Declaration/Power of Attorney; Sequence Listing Transmittal (1 pg), paper copy of Sequence Listing (6 pgs), this Certificate of Express Mail (1 pg), and a postpaid return postcard receipt.

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

February 20, 2002*(Date)*Philip Fantasia*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)*EL 805 319 583 US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fallon, et al.

Serial No: To Be Assigned

Filed: February 20, 2002

For: Biglycan And Related
Therapeutics And Methods Of Use

Art Unit: To Be Assigned

Attorney Docket No. BURF-P02-006

Examiner: To Be Assigned

**TRANSMITTAL OF SEQUENCE LISTING IN COMPUTER READABLE
FORM IN COMPLIANCE WITH 37 C.F.R. §1.821(e)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In accordance with 37 C.F.R. §1.821(e), the content of the "Sequence Listing" in the above-referenced continuation-in-part utility patent application is identical to the sequence listing filed in the parent application, U.S. Serial No. 09/715836, filed November 17, 2000. Applicant respectfully requests that a copy of the sequence listing filed in the parent application be included in the above-identified application in lieu of a new C.R.F. No new matter has been added.

Date: February 20, 2002

Customer No: 28120
Docketing Specialist
Ropes & Gray
One International Place
Boston, MA 02110

Respectfully Submitted,

ROPE & GRAY


Matthew P. Vincent
Reg. No. 36,709